Tactile Systems Technology, Inc
Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management. Its core offerings address lymphedema, chronic venous insufficiency, and airway clearance therapy, with sales concentrated in the United States through a direct-to-patient and provider model.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaHome-use pneumatic compression devices for lymphedema and related venous disease.
Vest-based respiratory therapy devices used to help clear mucus in chronic lung conditions.
Tuotteet
Raportoitu · osuus liikevaihdosta- Lymphedema Products84,5 %
- Airway Clearance Products15,5 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells primarily to patients in the United States, with reimbursement and access shaped by physicians, payers, and durable medical equipment channels. Its products are used by people with chronic conditions such as lymphedema, chronic venous insufficiency, and respiratory disease, often after clinical referral and payer approval.
Buy Flexitouch Plus, Entre Plus, and Nimbl systems for home treatment of swelling and related symptoms.
Use compression therapy devices to manage venous disease and related edema.
Buy AffloVest systems for airway clearance in chronic respiratory conditions.
Influence product adoption through referrals, coverage decisions, and reimbursement pathways.
Strategia
The company’s strategy centers on expanding home-based treatment adoption for underserved chronic diseases through direct clinical and patient engagement. It emphasizes sales-force productivity, payer access, clinical evidence, and product expansion to strengthen its position in the U.S. home-therapy market.
A direct model helps the company control patient education, access, and conversion.
Coverage criteria and billing privileges are central to device adoption and revenue realization.
New devices broaden the addressable market and reduce reliance on a single product line.
Maantiede
The business is concentrated in the United States, which is both its main sales market and operating base. The company also maintains trademark registrations in several non-U.S. markets, but the disclosed revenue base is overwhelmingly U.S.-centric.
Riskit
The company depends heavily on Medicare coverage, payer criteria, and durable medical equipment accreditation, so reimbursement changes could materially affect demand and access. It also faces intense competition, technology change, and operational risks tied to direct sales, manufacturing, cybersecurity, and product performance.
- Medicare coverage and reimbursement changesVaikutus: KorkeaTodennäköisyys: Kohtalainen
A large share of patients rely on Medicare, so coverage criteria directly affect utilization and collections.
Kohdistuu: U.S. home-therapy revenue
- Competitive pressure in pneumatic compression and airway clearanceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Rivals with broader resources or distribution can pressure pricing, share, and customer acquisition.
Kohdistuu: Lymphedema and respiratory device markets
- Accreditation and licensing complianceVaikutus: KorkeaTodennäköisyys: Matala
The direct-to-patient model depends on maintaining DME certification and related approvals.
Kohdistuu: U.S. operating model
- Cybersecurity and IT disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Patient, billing, and operational systems are exposed to intrusion, outage, or data breach risk.
Kohdistuu: Commercial and reimbursement systems
- Product performance and recall riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Device defects can affect patient safety, trigger field actions, and damage reputation.
Kohdistuu: All device lines
Kirjanpito
Harkinnanvaraiset erätDevice sales and rentals require judgment on expected payment and timing of recognition.
Vaikutus: Can change reported revenue if payer or patient collections differ from estimates
Management discloses seasonal effects that can distort quarter-to-quarter comparisons.
Vaikutus: Affects revenue and expense comparability across periods
The AffloVest earn-out was remeasured to fair value until the earn-out period ended.
Vaikutus: Can create non-cash gains or losses in the income statement
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Electromed, Inc.
ELMD · Electromedical & Electrotherapeutic Apparatus
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
InfuSystem Holdings, Inc
INFU · Surgical & Medical Instruments & Apparatus
Teleflex Incorporated
TFX · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
AtriCure, Inc.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
Päivitetty: 24.9.2026